Key resistance-associated mutations in multidrug-resistant tuberculosis: a genomic study from Shanghai, China, with a focus on aminoglycosides
Abstract
The aminoglycosides are essential drugs in the treatment of multidrug-resistant tuberculosis. Antibiotic resistance of Mycobacterium tuberculosis is a major public health concern worldwide. Therefore, it is of great significance to characterize the mutations by which susceptible M. tuberculosis evolves into drug resistance. A total of 110 clinical isolates of MDR-TB were used for Whole-genome sequencing (WGS) and phenotypic drug susceptibility testing to aminoglycosides, including amikacin, kanamycin, and streptomycin. Among 110 clinical MDR-TB strains, 7 (6.36%) were cross-resistant to amikacin and kanamycin, and 81 (73.64%) were resistant to streptomycin. The resistance rates to rifabutin, streptomycin, moxifloxacin, ofloxacin, and ethambutol were observed in 79.09%, 73.64%,35.45%, 34.55%, and 30.91%, respectively. Among the 81 MDR-TB strains resistant to streptomycin, the MIC values of streptomycin against MDR-TB showed the following distribution: 61 strains (75.31%) demonstrated resistance with MICs ≥ 32 µg/ml. The rrs gene mutations were detected in 6 (85.71%; 6/7) of the amikacin/kanamycin-resistant isolates, with the most frequent mutation being A1401G. Mutations in the eis promoter were identified at two positions in 3 amikacin/kanamycin-susceptible and streptomycin-resistant isolates (-10G > A and - 37G > T). In 80.25% (65 out of 81) of streptomycin-resistant MDR-TB isolates, two types of amino acid substitutions associated with rpsL mutations were identified. K43R…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.